Literature DB >> 359098

Effects of varying radiation schedule, cyclophosphamide treatment, and duration of treatment in acute lymphoblastic leukaemia. Report to the Medical Research Council by the Working Party on Leukaemia in Childhood.

.   

Abstract

In a multicentre trial of treatment for acute lymphoblastic leukaemia the effects of three types of central nervous system prophylaxis, the inclusion of cyclophosphamide, and the total duration of chemotherapy were assessed. A schedule with a high dose of spinal irradiation (2400 rads) without intrathecal methotrexate was inferior to schedules with some (1000 rads) or no spinal irradiation but with intrathecal methotrexate. The addition of cyclophosphamide 600 mg/m2 given intravenously every 12 weeks was of no benefit and was possibly deleterious. There was no advantage in adding four 12-week courses of chemotherapy after eight courses (total duration two years) had been given. Girls fared significantly better than boys, the difference being only partly due to the occurrence of testicular relapse.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 359098      PMCID: PMC1607833          DOI: 10.1136/bmj.2.6140.787

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  1 in total

Review 1.  Extramedullary leukaemia.

Authors:  H O Hustu; R J Aur
Journal:  Clin Haematol       Date:  1978-06
  1 in total
  7 in total

Review 1.  Chemotherapy of childhood lymphoblastic leukaemia: the first 50 years.

Authors:  J Lilleyman
Journal:  Paediatr Drugs       Date:  1999 Jul-Sep       Impact factor: 3.022

2.  Current management of childhood acute lymphocytic leukemia.

Authors:  H Ekert
Journal:  Indian J Pediatr       Date:  1981 Jul-Aug       Impact factor: 1.967

3.  Uterine and ovarian leukaemic relapse during bone marrow remission in acute lymphoblastic leukaemia.

Authors:  B Cantwell; D Cantwell; J J Fennelly
Journal:  Postgrad Med J       Date:  1982-11       Impact factor: 2.401

Review 4.  An odyssey in search of a cure: the evolution of treatment of childhood acute lymphoblastic leukemia in the United Kingdom.

Authors:  V Saha; T Eden
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

5.  Sex variability in pediatric leukemia survival: large cohort evidence.

Authors:  L Holmes; J Hossain; M Desvignes-Kendrick; F Opara
Journal:  ISRN Oncol       Date:  2012-04-03

6.  Characterization of pediatric acute lymphoblastic leukemia survival patterns by age at diagnosis.

Authors:  Md Jobayer Hossain; Li Xie; Suzanne M McCahan
Journal:  J Cancer Epidemiol       Date:  2014-09-17

7.  Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemia.

Authors:  David T Teachey; Stephen P Hunger; Mignon L Loh
Journal:  Blood       Date:  2021-01-14       Impact factor: 22.113

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.